



Quality For All

## **Equinox Pharma Holding Limited (Equinox) increases its stake in Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E.**

**28 July 2021 | Cairo, Egypt**

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E., (RMDA.CA on the EGX), a leading Egyptian pharmaceutical company, announced today that its largest shareholder, Equinox, increased its existing stake in the company by 2.7% to 15.4%.

Commenting on the transaction, Equinox's Managing Director, Shamel Aboul Fadl, said: "Since our initial acquisition of Rameda ten years ago as part of a consortium of investors, to the company's successful public listing in 2019 and beyond, we are pleased to have been a part of Rameda's exceptional growth story over the last decade and continue to be excited about what lies ahead for company driven by its growth-oriented management team, established track record of accretive molecule acquisitions, attractive product portfolio, extensive production capabilities and its growing regional footprint"

"We look forward to further solidifying Rameda's decade-long relationship with our main shareholder, Equinox. We believe that the transaction underscores Equinox's continued confidence in Rameda's ability to deliver sustainable long-term growth and value creation, as it has done consistently over the last ten years", added Rameda's CEO, Dr. Amr Morsy

-Ends-

### **Investor Relations Contact:**

Yasmine Negm  
Rameda's Head of Investor Relations & Strategic Communications  
Email: [yasmine.negm@rameda.com](mailto:yasmine.negm@rameda.com)  
Mobile: +20(0) 1228505050

### **About Rameda**

Established in 1986, Rameda (RMDA.CA on EGX) is a leading Egyptian pharmaceutical company led by a team of professionals with extensive multinational experience. The company develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements and veterinary products. Rameda combines global standards with local insights and a customer-centric approach. It has developed a broad portfolio of products across multiple therapeutic areas by successfully leveraging its strong product portfolio with its accretive product acquisitions to become one of the fastest-growing pharmaceutical players in Egypt. The company produces its wide range of dosage forms at its three manufacturing facilities located at its industrial complex in Cairo's Sixth of October Industrial Zone.



Quality For All

---

## **Forward-Looking Statements**

This communication contains certain forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, and can be identified by the use of such words and phrases as "according to estimates", "anticipates", "assumes", "believes", "could", "estimates", "expects", "intends", "is of the opinion", "may", "plans", "potential", "predicts", "projects", "should", "to the knowledge of", "will", "would", or, in each case, their negatives, or other similar expressions that are intended to identify a statement as forward-looking. This applies, in particular, to statements containing information on future financial results, plans, or expectations regarding our business and management, our future growth or profitability and general economic and regulatory conditions and other matters affecting us.

Forward-looking statements reflect our management's ("Management") current views of future events, are based on Management's assumptions, and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. The occurrence or non-occurrence of an assumption could cause our actual financial condition and results of operations to differ materially from, or fail to meet expectations expressed or implied by, such forward-looking statements. Our business is subject to a number of risks and uncertainties that could also cause a forward-looking statement, estimate, or prediction to become inaccurate. These risks include fluctuations in the prices of raw materials or employee costs required by our operations, its ability to retain the services of certain key employees, its ability to compete successfully, changes in political, social, legal, or economic conditions in Egypt, worldwide economic trends, the impact of war and terrorist activity, inflation, interest rate and exchange rate fluctuations, and Management's ability to timely and accurately identify future risks to our business and manage the risks mentioned above.

Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly to the total figure given.